Jinchutha Duangdara

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 3

Top Topics

Cell Cycle Arrest

Vascular Smooth Muscle Cells

Top Venues

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Jinchutha Duangdara, Boonyakorn Boonsri, Apinya Sayinta, Kittiya Supradit, Pakpoom Thintharua, Supeecha Kumkate, Chinnawut Suriyonplengsaeng, Noppadol Larbcharoensub, Somkit Mingphruedhi, Narongsak Rungsakulkij, Paramin Muangkaew, Pongsatorn Tangtawee, Watoo Vassanasiri, Wikran Suragul, Tavan Janvilisri, Rutaiwan Tohtong, David Owen Bates, Kanokpan Wongprasert
CP-673451, a Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces Apoptosis in Opisthorchis viverrini -Associated Cholangiocarcinoma via Nrf2 Suppression and Enhanced ROS. Pharmaceuticals (Basel, Switzerland) 17 (1) (2023)
Jinchutha Duangdara, Boonyakorn Boonsri, Apinya Sayinta, Kittiya Supradit, Pakpoom Thintharua, Supeecha Kumkate, Chinnawut Suriyonplengsaeng, Noppadol Larbcharoensub, Somkit Mingphruedhi, Narongsak Rungsakulkij, Paramin Muangkaew, Pongsatorn Tangtawee, Watoo Vassanasiri, Wikran Suragul, Tavan Janvilisri, Rutaiwan Tohtong, David Owen Bates, Kanokpan Wongprasert
CP-673451, a Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces Apoptosis in Opisthorchis viverrini -Associated Cholangiocarcinoma via Nrf2 Suppression and Enhanced ROS. Pharmaceuticals (Basel, Switzerland) 17 (1) (2023)
Jinchutha Duangdara, Boonyakorn Boonsri, Apinya Sayinta, Kittiya Supradit, Pakpoom Thintharua, Supeecha Kumkate, Chinnawut Suriyonplengsaeng, Noppadol Larbcharoensub, Somkit Mingphruedhi, Narongsak Rungsakulkij, Paramin Muangkaew, Pongsatorn Tangtawee, Watoo Vassanasiri, Wikran Suragul, Tavan Janvilisri, Rutaiwan Tohtong, David Owen Bates, Kanokpan Wongprasert
CP-673451, a Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces Apoptosis in Opisthorchis viverrini -Associated Cholangiocarcinoma via Nrf2 Suppression and Enhanced ROS. Pharmaceuticals (Basel, Switzerland) 17 (1) (2023)